Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors-Reference-Cited by-同舟云学术

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

Published:2010-01 Issue:1 Volume:20 Page:245-254
ISSN:1015-6305
Container-title:Brain Pathology
language:en
Short-container-title:

Author:

Capper David,WeiÃert Susanne,Balss JÃ¶rg,Habel Antje,Meyer Jochen,JÃ¤ger Diana,Ackermann Ulrike,Tessmer Claudia,Korshunov Andrey,Zentgraf Hanswalter,Hartmann Christian,Von Deimling Andreas

Publisher

Wiley

Subject

Clinical Neurology,Pathology and Forensic Medicine,General Neuroscience

Reference22 articles.

1. Analysis of the IDH1 codon 132 mutation in brain tumors;Balss;Acta Neuropathol,2008

2. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors;Bleeker;Hum Mutat,2009

3. Monoclonal antibody specific for IDH1 R132H mutation;Capper;Acta Neuropathol,2009

4. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas;Hartmann;Acta Neuropathol,2009

Cited by 454 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation;Pathology - Research and Practice;2024-09

2. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives;Cancers;2024-08-02

3. Primary spinal cord gliomas: Pathologic features associated with prognosis;Journal of Neuropathology & Experimental Neurology;2024-07-29

4. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma;Acta Neuropathologica;2024-07-16

5. Temozolomide based treatment in glioblastoma: 6 vs. 12 months;Oncology Letters;2024-07-02